These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32651161)

  • 1. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.
    Camu W; Mickunas M; Veyrune JL; Payan C; Garlanda C; Locati M; Juntas-Morales R; Pageot N; Malaspina A; Andreasson U; Kirby J; Suehs C; Saker S; Masseguin C; De Vos J; Zetterberg H; Shaw PJ; Al-Chalabi A; Leigh PN; Tree T; Bensimon G
    EBioMedicine; 2020 Sep; 59():102844. PubMed ID: 32651161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
    Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
    PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.
    Hartemann A; Bensimon G; Payan CA; Jacqueminet S; Bourron O; Nicolas N; Fonfrede M; Rosenzwajg M; Bernard C; Klatzmann D
    Lancet Diabetes Endocrinol; 2013 Dec; 1(4):295-305. PubMed ID: 24622415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
    Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
    Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosis.
    Alarcan H; Bruno C; Emond P; Raoul C; Vourc'h P; Corcia P; Camu W; Veyrune JL; Garlanda C; Locati M; Juntas-Morales R; Saker S; Suehs C; Masseguin C; Kirby J; Shaw P; Malaspina A; De Vos J; Al-Chalabi A; Leigh PN; Tree T; Bensimon G; Blasco H
    Ann N Y Acad Sci; 2024 Jun; 1536(1):82-91. PubMed ID: 38771698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
    Koch JC; Leha A; Bidner H; Cordts I; Dorst J; Günther R; Zeller D; Braun N; Metelmann M; Corcia P; De La Cruz E; Weydt P; Meyer T; Großkreutz J; Soriani MH; Attarian S; Weishaupt JH; Weyen U; Kuttler J; Zurek G; Rogers ML; Feneberg E; Deschauer M; Neuwirth C; Wuu J; Ludolph AC; Schmidt J; Remane Y; Camu W; Friede T; Benatar M; Weber M; Lingor P;
    Lancet Neurol; 2024 Nov; 23(11):1133-1146. PubMed ID: 39424560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Benatar M; Hansen T; Rom D; Geist MA; Blaettler T; Camu W; Kuzma-Kozakiewicz M; van den Berg LH; Morales RJ; Chio A; Andersen PM; Pradat PF; Lange D; Van Damme P; Mora G; Grudniak M; Elliott M; Petri S; Olney N; Ladha S; Goyal NA; Meyer T; Hanna MG; Quinn C; Genge A; Zinman L; Jabari D; Shoesmith C; Ludolph AC; Neuwirth C; Nations S; Shefner JM; Turner MR; Wuu J; Bennett R; Dang H; Sundgreen C;
    Lancet Neurol; 2024 Jul; 23(7):687-699. PubMed ID: 38782015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
    Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
    J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
    Cudkowicz ME; Titus S; Kearney M; Yu H; Sherman A; Schoenfeld D; Hayden D; Shui A; Brooks B; Conwit R; Felsenstein D; Greenblatt DJ; Keroack M; Kissel JT; Miller R; Rosenfeld J; Rothstein JD; Simpson E; Tolkoff-Rubin N; Zinman L; Shefner JM;
    Lancet Neurol; 2014 Nov; 13(11):1083-1091. PubMed ID: 25297012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Cudkowicz M; Genge A; Maragakis N; Petri S; van den Berg L; Aho VV; Sarapohja T; Kuoppamäki M; Garratt C; Al-Chalabi A;
    Lancet Neurol; 2021 Oct; 20(10):821-831. PubMed ID: 34536404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.
    Vucic S; Menon P; Huynh W; Mahoney C; Ho KS; Hartford A; Rynders A; Evan J; Evan J; Ligozio S; Glanzman R; Hotchkin MT; Kiernan MC
    EClinicalMedicine; 2023 Jun; 60():102036. PubMed ID: 37396808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
    Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
    Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
    Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.
    Al-Chalabi A; Shaw P; Leigh PN; van den Berg L; Hardiman O; Ludolph A; Aho VV; Sarapohja T; Kuoppamäki M
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1165-1170. PubMed ID: 31315908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
    Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
    BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
    Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease.
    Zhao TX; Sriranjan RS; Tuong ZK; Lu Y; Sage AP; Nus M; Hubsch A; Kaloyirou F; Vamvaka E; Helmy J; Kostapanos M; Jalaludeen N; Klatzmann D; Tedgui A; Rudd JHF; Horton SJ; Huntly BJP; Hoole SP; Bond SP; Clatworthy MR; Cheriyan J; Mallat Z
    NEJM Evid; 2022 Jan; 1(1):EVIDoa2100009. PubMed ID: 38319239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis.
    Thonhoff JR; Berry JD; Macklin EA; Beers DR; Mendoza PA; Zhao W; Thome AD; Triolo F; Moon JJ; Paganoni S; Cudkowicz M; Appel SH
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36038262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.